La lecture en ligne est gratuite
Le téléchargement nécessite un accès à la bibliothèque YouScribe
Tout savoir sur nos offres
Télécharger Lire

Partagez cette publication

OBN Adds World Class Pharma and VC Figures
to its Thematic Advisory Panels
PR Newswire
OXFORD, England, June 26, 2012
OXFORD, England
June 26, 2012
/PRNewswire/ --
OBN, the not-for-profit business network which provides comprehensive
support for bioscience businesses in the 'Golden Triangle' biocluster and
beyond, is pleased to announce that it has established two new high level
Advisory Panels. The two Boards draw on leading experts from across the
industry and have been created in order to maintain OBN's leadership position
in program development at BioTrinity,
3rd Largest Annual Partnering
and Investment Conference.
The Business Development and Licensing (BD&L) Advisory Panel contains
participants from big pharma through to small biotech BD&L executives,
including Amgen, Astellas Pharma Europe, Biogen Idec, Bristol-Myers Squibb,
Crescendo Biologics, Kymab, Polytherics, Prosidion, Shire and Takeda
Pharmaceuticals Europe.
Dr Jon Rees, CEO of OBN, said:
"Only by listening to key industry executives
embedded in the deal-making and licensing environment can we respond to the
needs and interests of the members in our network and continue to deliver
cutting edge content to the participants at our networking events and
The Investor Advisory Panel draws on BioTrinity's long-standing role of bringing
a wide range of international investors together with R&D companies. It
includes participants from the UK,
and the US and from traditional
venture capital and the corporate venturing worlds. Members include 3i plc,
Abbott Biotech Ventures, Apposite Capital LLP, Boehringer Ingelheim Venture
Fund GmbH, Credit Agricole Private Equity (CAPE), Edmond de Rothschild
Investment Partners, Index Ventures, MedImmune Ventures, Merck Serono
Ventures, Sofinnova Partners, SR One (GSK), and Takeda Ventures.
Already the panel participants have given their first round of feedback and
suggestions for next year's BioTrinity panels and this will be developed to
release the preliminary BioTrinity 2013 program in
December 2012
. Combined
with OBN's recent 'Life Sciences, New Money' series of networking events and
breakfasts in
, the advanced program
development for BioTrinity 2013 maintains OBN's leadership position in
providing comprehensive support for the UK bioindustry.
Dr Jon Rees, CEO of OBN, said:
"I am delighted with the levels of energy and
commitment the investment community, our 200 members, the wider industry
and my team are feeding into ensuring our offer continues to be more relevant
and more exciting than ever. This synergy will benefit us all."
About OBN
OBN is a not-for-profit business network which provides comprehensive support
for its member biotech and medtech companies in the
biocluster and the rest of the UK. Our activities can be summarised as
networking, partnering, group purchasing, and fundraising advice. Through its
delivery of
fastest growing biopartnering and investment conference,
BioTrinity, OBN generates more R&D-company-to-investor interactions than
anyone else in
. OBN is sponsored by Shire, as Corporate Patron, and
Corporate Sponsors MEPC, Manches LLP, James Cowper, George James, Ernst &
Young, Interea International, SRG, FOCUS Insurance, Ardington Archives, World
Courier and Citigate Dewe Rogerson as well as by its extensive membership of
R&D companies and other companies across the entire life sciences industry
ecosystem. OBN counts more than 200 companies amongst its membership,
which is growing over 40% per year.
For further information on OBN and its activities, please visit:
About the Advisory Panels
The two Advisory Panels contain representatives from the following companies:
Credit Agricole Private Equity (CAPE), GlaxoSmithKline, Edmond de Rothschild
Investment Partners (EdRIP), MedImmune Ventures, 3i plc, Apposite Capital
LLP, Index Ventures, Boehringer Ingelheim Venture Fund GmbH, Sofinnova
Partners, Merck Serono Ventures, Abbott Biotech Ventures, SR One
(GlaxoSmithKline), GlaxoSmithKline, Takeda Ventures.
Business Development and Licensing
Amgen, Astellas Pharma Europe, Biogen Idec, Bristol-Myers Squibb, Crescendo
Biologics, Kymab, Prosidion , Shire, Takeda Pharmaceuticals Europe,
Andy Smith, Director of Investor Relations and PR
Tel: +44(0)845-5049715
Citigate Dewe Rogerson
Chris Gardner/Nina Enegren
T: +44(0)20-7638-9571 /
Un pour Un
Permettre à tous d'accéder à la lecture
Pour chaque accès à la bibliothèque, YouScribe donne un accès à une personne dans le besoin